How should intranasal antihistamines be used to treat allergic rhinitis in patients aged ≥ 6 years, including dosing, contraindications, and next steps if symptoms persist?

Intranasal Antihistamines for Allergic Rhinitis in Patients ≥6 Years

Intranasal antihistamines (azelastine or olopatadine) are effective options for treating allergic rhinitis in patients aged ≥6 years, offering rapid symptom relief within minutes and superior efficacy for nasal congestion compared to oral antihistamines, though they are generally less effective than intranasal corticosteroids as monotherapy. 1, 2

Available Agents and FDA-Approved Dosing

Olopatadine (Patanase) 0.6%

• Ages 6-11 years: 1 spray per nostril twice daily 1
• Ages ≥12 years: 2 sprays per nostril twice daily 1
• Indication: Seasonal allergic rhinitis 1

Azelastine 0.1% (Astelin)

• Ages 6-11 years: 1 spray per nostril twice daily 1
• Ages ≥12 years: 1-2 sprays per nostril twice daily OR 2 sprays once daily 1
• Indication: Seasonal allergic rhinitis and vasomotor rhinitis 1

Azelastine 0.15% (Astepro)

• Ages 6-11 years: 1 spray per nostril twice daily 1
• Ages ≥12 years: 1-2 sprays per nostril twice daily OR 2 sprays once daily 1
• Indication: Seasonal and perennial allergic rhinitis 1

Contraindications

There are no specific contraindications listed for intranasal antihistamines. 1 However, these agents are not approved for children younger than 6 years. 1

Clinical Positioning and Efficacy

When to Use as First-Line Therapy

• Episodic or intermittent symptoms: Intranasal antihistamines have rapid onset of action (within minutes), making them ideal for as-needed use or pretreatment before allergen exposure 1, 2
• Nasal congestion predominance: More efficacious than oral antihistamines specifically for nasal congestion 1
• Patient preference for rapid relief: Onset occurs within minutes compared to hours-to-days for intranasal corticosteroids 3, 2

Comparative Efficacy

• Superior to oral antihistamines: Multiple randomized controlled trials demonstrate equality or superiority to oral second-generation antihistamines for nasal symptoms 1, 4
• Less effective than intranasal corticosteroids: Intranasal corticosteroids remain more effective for overall symptom control as monotherapy 1, 5, 2
• Effective even after oral antihistamine failure: Patients who fail oral antihistamine treatment may still benefit from intranasal antihistamines 1

Common Side Effects and Management

Expected Adverse Effects

• Bitter taste: Most common complaint, varies between formulations 1
• Epistaxis (nosebleeds): Occurs but generally mild 1
• Somnolence: Modern studies show rates of 0.4-3%, similar to placebo (0.3-10%) and oral antihistamines (1.3-14%) 1
• Headache: Reported in clinical trials 1

Critical Pitfall: Taste Aversion

If a patient experiences bitter taste but has symptomatic benefit, trial a different intranasal antihistamine formulation rather than discontinuing the class entirely, as taste varies significantly between products. 1 The azelastine 0.15% formulation includes sorbitol and sucralose specifically to improve taste. 1

Monitoring for Somnolence

Monitor patients at initiation for signs of somnolence and schedule follow-up to assess response and side effects, though clinically significant sedation is uncommon at recommended doses. 1

Next Steps if Symptoms Persist

Escalation Algorithm

Step 1: Optimize Current Therapy

• Ensure proper administration technique (spray directed away from nasal septum) 6
• Verify adherence to twice-daily dosing 1
• Consider switching to alternative intranasal antihistamine formulation if taste is limiting compliance 1

Step 2: Add Intranasal Corticosteroid

• Combination therapy (intranasal antihistamine + intranasal corticosteroid) is more effective than either agent alone for moderate-to-severe allergic rhinitis 1, 5, 2
• Fixed-combination products (e.g., azelastine/fluticasone) provide convenience and demonstrated superior efficacy 1, 5
• For ages ≥12 years: Azelastine/fluticasone (Dymista) 1 spray per nostril twice daily 1

Step 3: Consider Alternative or Additional Therapies

• Oral second-generation antihistamines may be added for eye symptoms 1
• Evaluate for allergen immunotherapy if symptoms remain poorly controlled on combination therapy 1, 7
• Do NOT use oral leukotriene receptor antagonists (montelukast) as primary therapy—they are less effective than intranasal antihistamines and intranasal corticosteroids 1

Special Considerations

Proper Administration Technique

• Direct spray away from nasal septum to minimize epistaxis risk 6
• Examine nasal septum periodically to ensure no mucosal erosions 6

Pregnancy Considerations

• Oral decongestants should be avoided during first trimester, but intranasal antihistamines may be considered 7

Cost and Access

• All intranasal antihistamines require prescription 1
• Higher cost relative to oral antihistamines may affect adherence 1
• Generic oral antihistamines are available over-the-counter as cost-effective alternatives for mild symptoms 1